Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study

Fig. 1

IrAEs and efficacy. Kaplan–Meier curves for progression-free survival in patients treated with pembrolizumab and chemotherapy (a) and those treated with pembrolizumab monotherapy (b). Kaplan–Meier curves with 12-week landmark analysis for progression-free survival in patients treated with pembrolizumab and chemotherapy (c) and those treated with pembrolizumab monotherapy (d)

Back to article page